Hematology
Indications for Use
Azacitidine (for subcutaneous or intravenous administration) is indicated for the treatment of adult patients with the following subtypes of French-American-British (FAB) myelodysplastic syndrome (MDS): refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (in the presence of neutropenia or thrombocytopenia, as well as in the presence of transfusion requirements), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMML). Azacitidine is also indicated for the treatment of children 1 month of age and older with newly diagnosed juvenile myelomonocytic leukemia (JMML).
Dosage 15 mg price 220$
Colorectal cancer
Lansurf is indicated as monotherapy for adult patients with metastatic colorectal cancer who have previously undergone or are ineligible for existing therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as well as anti-VEGF and anti-EGFR agents.
Gastric cancer
Lansurf is indicated as monotherapy for adult patients with metastatic gastric cancer, including patients with gastroesophageal junction adenocarcinoma, who have previously received at least two systemic therapies at disease progression.
Showing
Chronic lymphocytic leukemia (CLL)
Gazyva® in combination with chlorambucil is indicated for the treatment of adult patients with chronic lymphocytic leukemia, who have not previously recovered from the treatment and may have a concomitant illness that makes it impossible to carry out therapy based on fludarabine at higher doses.
Follicular lymphoma (FL)
Gazyva® in combination with chemotherapy with further supportive therapy with the drug Gazyva®, in the available version, is indicated for the treatment of patients with previously untreated extended follicular lymphoma.
Gazyva® in combination with bendamustine followed by supportive therapy with Gazyva® is indicated for the treatment of patients with follicular lymphoma who do not respond to treatment rituximab or combination therapy, which included rituximab, or illness progressed within an hour or over a period of 6 months after treatment with rituximab or after combination therapy, which included rituximab.
Indication
Pomalidomide in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior course of treatment that included lenalidomide.
Pomalidomide in combination with dexamethasone is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have previously received at least two courses of treatment with lenalidomide and bortezomib and who have disease progression on the background of the last therapy.
All Europe delivery. Shipping time 7-10 days. Price for shipping individual for each country. Usually 40-50 euro. Payment when sending the goods.
Worldwide shipping possible too.
Zoladex 10.8 - $180 Zoladex 3.6 - $54
$350
